Linkster Therapeutics is at the forefront of advancing targeted therapeutics through its innovative Flycode® platform, which focuses on the development of precision medicines tailored to specific targets, tissues, and patients. This platform enables the profiling of large pools of peptide barcoded antibodies in various environments, including in vitro, in vivo, and in silico. By employing translational antibody engineering, Linkster Therapeutics aims to overcome common challenges in drug development, such as the inefficiencies of translating in vitro candidates to clinical applications. Their approach emphasizes the importance of tissue-specific delivery, which minimizes off-target effects and enhances the efficacy of antibody drugs.

The company’s pipeline leverages its proprietary Flycode technology to explore new opportunities for large molecules, proteins, and conjugates of small, RNA, and DNA molecules that require improved targeting. Linkster Therapeutics is committed to developing first-in-class or best-in-class precision medicines and actively seeks strategic partnerships with global pharmaceutical and biotech companies to advance their drug candidates. Their focus on cell surface targets, including GPCRs and SLC transporters, further enhances their ability to create pharmacologically improved antibodies and antibody conjugates, ultimately aiming for better therapeutic outcomes in areas of significant medical need.

Switzerland

Linkster is a swiss-based precision medicine company focusing on multi-specific antibodies and tissue-specific delivery. The company creates next generation targeted therapeutics through its Flycode® platform for high-throughput cellular and in vivo antibody engineering.

Linkster has entered into several agreements with pharmaceutical and biotech companies and is actively seeking further partnerships for the co-development of innovative therapeutic products.

Linkster Therapeutics

Company Details